Chapter 085. Neoplasms of the Lung (Part 13)

Table 85-5 Randomized Studies of Adjuvant Chemotherapy in NSCLCStu dyTreatment mberNu of Year5edianM zardHa ValuepPatientsSurvival Survival Ratio (%) (95% CI)EC OGSurgery242 9% 246339 months vs.0.9 3 (0.74– .5603590 →RT vs. Surgery + post-op concurrent(II–IIIA)38 1.18)3 RT + cis/etoposide 3% monthsALSurgery603 1% 6065 RN 60.9 (0.8– .590PI (I–IIIA) alone vs. Surgery + post-opmitomycin/vindesin e/cisplatin 3%41.1)BigSurgery18933 months1.0 2 (0.77– .90 1.35)0Lung Trial alone vs. Surgery + 192 (I–IIIB) post-op34 chemotherapyamonthsIALSurgery405 0% 3614 RN0.8 6 (0.76– 0.03 0.98)...
Nội dung trích xuất từ tài liệu:
Chapter 085. Neoplasms of the Lung (Part 13) Chapter 085. Neoplasms of the Lung (Part 13) Table 85-5 Randomized Studies of Adjuvant Chemotherapy in NSCLC Stu Treatment Nu 5- M Ha pdy mber of Year edian zard Value Patients Survival Survival Ratio (%) (95% CI) EC Surgery 242 3 39 0.9 0OG 3590 →RT vs. Surgery + 9% months 3 (0.74– .56 246(II–IIIA) post-op concurrent vs. 38 1.18) 3 RT + cis/etoposide months 3% AL Surgery 603 5 N 0.9 0PI (I–IIIA) alone vs. Surgery + 1% R 6 (0.8– .59 606 post-op mitomycin/vindesin 4 1.1) e/cisplatin 3% Big Surgery 189 33 1.0 0Lung Trial alone vs. Surgery + months 2 (0.77– .90 192(I–IIIB) post-op 1.35) 34 a chemotherapy months IAL Surgery 405 4 N 0.8